78,499 Personalis, Inc. $PSNL Shares Sold by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. reduced its holdings in Personalis, Inc. (NASDAQ:PSNL) by 18.8% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 338,989 shares of the company’s stock after selling 78,499 shares during the quarter. Sumitomo Mitsui Trust Group Inc.’s holdings in Personalis were worth $5,519,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Merck & Co. Inc. purchased a new stake in Personalis in the 2nd quarter valued at about $188,202,236. BlackRock Inc. acquired a new position in shares of Personalis during the 2nd quarter valued at about $94,905,000. Bank of America Corp DE purchased a new position in shares of Personalis during the 2nd quarter worth about $24,395,000. AIGH Capital Management LLC purchased a new position in shares of Personalis during the 2nd quarter worth about $22,981,000. Finally, Dimensional Fund Advisors LP boosted its position in shares of Personalis by 8.4% in the first quarter. Dimensional Fund Advisors LP now owns 1,066,248 shares of the company’s stock worth $6,791,000 after acquiring an additional 83,074 shares during the last quarter. 61.91% of the stock is owned by institutional investors and hedge funds.

Personalis Stock Performance

PSNL traded up $0.24 on Friday, reaching $15.79. 3,000,174 shares of the company’s stock were exchanged, compared to its average volume of 2,460,835. The company’s 50 day moving average is $16.18 and its 200-day moving average is $11.48. The company has a market cap of $1.65 billion, a price-to-earnings ratio of -13.50 and a beta of 2.40. Personalis, Inc. has a twelve month low of $4.95 and a twelve month high of $18.89.

Personalis (NASDAQ:PSNL) last released its quarterly earnings data on Wednesday, November 4th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.06). Personalis had a negative return on equity of 46.47% and a negative net margin of 153.84%. The business had revenue of $25.60 million for the quarter, compared to analysts’ expectations of $21.54 million.

Insider Buying and Selling at Personalis

In other Personalis news, CMO Richard Chen sold 3,998 shares of the firm’s stock in a transaction dated Friday, September 18th. The stock was sold at an average price of $16.22, for a total value of $64,847.56. Following the transaction, the chief marketing officer directly owned 169,882 shares of the company’s stock, valued at $2,755,486.04. This trade represents a 2.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Stephen Moore sold 2,068 shares of the business’s stock in a transaction dated Friday, September 18th. The stock was sold at an average price of $16.22, for a total value of $33,542.96. Following the transaction, the senior vice president owned 90,257 shares in the company, valued at approximately $1,463,968.54. This represents a 2.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 16,456 shares of company stock worth $266,916. Insiders own 4.20% of the company’s stock.

Wall Street Analyst Weigh In

PSNL has been the subject of a number of recent analyst reports. Lake Street Capital downgraded shares of Personalis from a “buy” rating to a “hold” rating and set a $16.25 target price for the company. in a report on Monday, July 20th. TD Cowen reiterated a “buy” rating on shares of Personalis in a report on Wednesday, July 15th. BTIG Research lowered shares of Personalis from a “buy” rating to a “neutral” rating in a report on Tuesday, October 6th. UBS Group cut shares of Personalis from a “buy” rating to a “neutral” rating in a research note on Tuesday, October 6th. Finally, Craig Hallum lowered Personalis from a “buy” rating to a “hold” rating and set a $16.25 target price on the stock. in a research report on Monday, August 24th. Two analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $15.29.

Personalis Company Profile

Personalis, Inc is a genomics company focused on applying advanced sequencing and bioinformatics to cancer research and precision medicine. The company develops tests and data platforms designed to help researchers and clinicians characterize tumors, monitor disease, and support the development of targeted therapies.

Its product portfolio includes the NeXT Platform, which analyzes tumor and normal DNA and RNA to provide a detailed view of cancer biology, as well as products such as NeXT Dx, NeXT Liquid Biopsy, and NeXT Personal.